Chih‐Wei Lin
Amgen (United States)(US)
Publications by Year
Research Areas
Hepatitis C virus research, HIV/AIDS drug development and treatment, Lung Cancer Research Studies, Systemic Lupus Erythematosus Research, Lung Cancer Treatments and Mutations
Most-Cited Works
- → Glecaprevir–Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection(2018)430 cited
- → Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial(2017)339 cited
- → Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct‐acting antiviral treatment(2017)201 cited
- → Glecaprevir/pibrentasvir for 8 weeks in treatment-naïve patients with chronic HCV genotypes 1–6 and compensated cirrhosis: The EXPEDITION-8 trial(2019)151 cited
- → Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct‐acting antiviral treatment failure(2017)137 cited
- → Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Adolescents With Chronic Hepatitis C Virus: Part 1 of the DORA Study(2019)106 cited
- → Oral vaccination with recombinant Listeria monocytogenes expressing human papillomavirus type 16 E7 can cause tumor growth in mice to regress(2002)57 cited
- → Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of ABT-493: A First-In-Human Study(2016)27 cited
- → Pharmacokinetics, Safety, and Tolerability Following Single and Multiple Doses of Pibrentasvir in a First‐in‐Human Study(2017)27 cited
- → Pharmacokinetic Interactions and Safety of Coadministration of Glecaprevir and Pibrentasvir in Healthy Volunteers(2017)20 cited